1895 related articles for article (PubMed ID: 8529289)
1. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
2. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of 26-succinylbryostatin 1.
Bignami GS; Wagner F; Grothaus PG; Rustagi P; Davis DE; Kraft AS
Biochim Biophys Acta; 1996 Jul; 1312(3):197-206. PubMed ID: 8703988
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
6. Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation.
Mackanos EA; Pettit GR; Ramsdell JS
J Biol Chem; 1991 Jun; 266(17):11205-12. PubMed ID: 1904062
[TBL] [Abstract][Full Text] [Related]
7. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
8. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
9. The antineoplastic bryostatins affect human basophils and mast cells differently.
Patella V; Casolaro V; Ciccarelli A; Pettit GR; Columbo M; Marone G
Blood; 1995 Mar; 85(5):1272-81. PubMed ID: 7532037
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study.
Gonzalez R; Ebbinghaus S; Henthorn TK; Miller D; Kraft AS
Melanoma Res; 1999 Dec; 9(6):599-606. PubMed ID: 10661772
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of bryostatins and phorbol esters on arachidonic acid metabolite release and epidermal growth factor binding in C3H 10T1/2 cells.
Dell'Aquila ML; Herald CL; Kamano Y; Pettit GR; Blumberg PM
Cancer Res; 1988 Jul; 48(13):3702-8. PubMed ID: 3132318
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
[TBL] [Abstract][Full Text] [Related]
13. A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1.
Carr ME; Carr SL; Grant S
Anticancer Drugs; 1995 Jun; 6(3):384-91. PubMed ID: 7670135
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
Hornung RL; Pearson JW; Beckwith M; Longo DL
Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
[TBL] [Abstract][Full Text] [Related]
15. Bryostatins trigger human polymorphonuclear neutrophil and monocyte oxidative metabolism: association with in vitro antineoplastic activity.
Esa AH; Warren JT; Hess AD; May WS
Res Immunol; 1995; 146(6):351-61. PubMed ID: 8719659
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
[TBL] [Abstract][Full Text] [Related]
17. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Jones RJ; Sharkis SJ; Miller CB; Rowinsky EK; Burke PJ; May WS
Blood; 1990 Mar; 75(6):1319-23. PubMed ID: 2310830
[TBL] [Abstract][Full Text] [Related]
18. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia.
Lilly M; Brown C; Pettit G; Kraft A
Leukemia; 1991 Apr; 5(4):283-7. PubMed ID: 2027297
[TBL] [Abstract][Full Text] [Related]
19. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Wang S; Wang Z; Grant S
Mol Pharmacol; 2003 Jan; 63(1):232-42. PubMed ID: 12488556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]